Severe sulfonylurea-induced hypoglycemia: A problem of uncritical prescription and deficiencies of diabetes care in geriatric patients

Expert Opinion on Drug Safety

Volumn 9, Issue 5, 2010, Pages 675-681

  Holstein, Andreas ^a   Hammer, Claude ^a   Hahn, Michael ^a   Kulamadayil, Nidhi Su Ann ^a   Kovacs, Peter ^b  

^a Lippe Detmold Clinic   (Germany)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

Glibenclamide; Glimepiride; Incidence; Severe hypoglycemia; Sulfonylurea

Indexed keywords

CREATININE; GLIBENCLAMIDE; GLIMEPIRIDE; GLIQUIDONE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; SULFONYLUREA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DEMENTIA; DIABETES EDUCATION; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG CONTRAINDICATION; FEMALE; GERIATRIC PATIENT; GLUCOSE BLOOD LEVEL; HEART FAILURE; HOME CARE; HUMAN; HYPOGLYCEMIA; INCIDENCE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NURSING HOME; POLYPHARMACY; PRESCRIPTION; RISK FACTOR;

AGE FACTORS; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE SELF-MONITORING; COMORBIDITY; DIABETES MELLITUS, TYPE 2; FEMALE; GERMANY; GLYBURIDE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INAPPROPRIATE PRESCRIBING; INCIDENCE; INDEPENDENT LIVING; KIDNEY DISEASES; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NURSING HOMES; PATIENT EDUCATION AS TOPIC; PROSPECTIVE STUDIES; SULFONYLUREA COMPOUNDS;

EID: 77955963898     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.2010.492777     Document Type: Article

References (37)

1. Holstein A, Plaschke A, Egberts E-H. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 2001;17:467-473
2. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-139
3. Whitmer RA, Karter AJ, Yaffe K, et al. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 2009;301:1565-1572
4. Evans JM, Ogston SA, Emslie-Smith A, et al. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 2006;49:930-936
5. Tzoulaki I, Molokhia M, Curcin V, et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 2009;339:b4731
6. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009;52:1176-1180
7. Libby G, Donnelly LA, Donnan PT, et al. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009;32:1620-1625
8. Holstein A, Plaschke A, Vogel M-Y, Egberts E-H. Prehospital management of diabetic emergencies - a population-based intervention study. Acta Anaesthesiol Scand 2003;47:610-615
9. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41
10. Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005;67:2089-2100
11. WHO. BMI Classification. Available from:: http://apps.who.int/bmi/index. jsp
12. Folstein MF, Folstein SE, McHugh PR. Mini-mental state (a practical method for grading the state of patients for the clinician). J Psychiatr Res 1975;12:189-198
13. Leese GP, Wang J, Broomhall J, et al. for the DARTS/MEMO Collaboration. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes. Diabetes Care 2003;26:1176-1180
14. Asplund K, Wiholm B-E, Lithner F. Glibenclamide-associated hypoglycaemia: a report on 57 cases. Diabetologia 1983;24:412-417
15. Girardin E, Vial T, Pham E, Evreux JC. Hypoglycemia induced by oral hypoglycemic agents. Records of the French Regional Pharmacovigilance Centers 1985-1990. Ann Med Interne 1992;143:11-17
16. Greco D, Oisciotta M, Gambina F, et al. Severe hypoglycaemia leading to hospital admission in type 2 diabetic patients aged 80 years or older. Exp Clin Endocrinol Diabetes 2010. [Epub ahead of print]
17. American Diabetes Association. Standards of medical care in diabetes-2010. Diabetes Care 2010;33(Suppl 1):S11-61
18. Abbatecola AM, Paolisso G. Diabetes care targets in older persons. Diabetes Res Clin Pract 2009;86(Suppl 1):S35-40
19. Vischer UM, Bauduceau B, Bourdel-Marchasson I, et al. A call to incorporate the prevention and treatment of geriatric disorders in the management of diabetes in the elderly. Diabetes Metab 2009;35:168-177
20. Bremer J, Jauch-Chara K, Hallschmid M, et al. Hypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes. Diabetes Care 2009;32:1513-1537
21. Thomson TFJ, Masson EA, Leeming JT. Lack of knowledge of symptoms of hypoglycaemia by elderly diabetic patients. Age Ageing 1991;20:404-406
22. European Diabetes Working Party for Older People: Clinical Guidelines for Type 2 Diabetes Mellitus, 2004. Available from: http://www.eugms.org/index.php? pid=30
23. Abaterusso C, Lupo A, Ortalda V, et al. Treating elderly people with diabetes and stages 3 and 4 chronic kidney disease. Clin J Am Soc Nephrol 2008;3:1185-1194
24. Gerstein HC, Miller ME, Byington RP, et al. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559
25. Patel A, MacMahon S, Chalmers J, et al. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572
26. Currie CJ, Peters JR, Tynan A, et al. Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet 2010;375:481-489
27. Thomas C, Thomas L. Renal failure - measuring the glomerular filtration rate. Dtsch Arztebl Int 2009;106(51-52):849-854
28. Niemi M, Cascorbi I, Timm R, et al. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin Pharmacol Ther 2002;72:326-332
29. Holstein A, Beil W. Oral antidiabetic drug metabolism: pharmacogenomics and drug interactions. Expert Opin Drug Metab Toxicol 2009;5:225-241
30. Amiel SA, Dixon T, Mann R, et al. Hypoglycaemia in type 2 diabetes. Diab Med 2008;25:245-254
31. Mengel K. Antidiabetika. In: Schwabe U, Paffrath D, editors, Arzneimittelverordnungs-Report 2009. Springer Verlag, Heidelberg; 2009. p. 327-329
32. Holstein A, Plaschke A, Egberts E-H. Incidence and costs of severe hypoglycemia. Diabetes Care 2002;25:2109-2110
33. Available from: http://www.deutsche-diabetes-gesellschaft. deStellungnahme Blutzuckerteststreifen bei Patienten mit Diabetes mellitus Typ 2
34. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-1705
35. Pratley RE, Rosenstock J, Pi-Sunyer FX, et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care 2007;30:3017-3022
36. Ferrannini E, Fonseca V, Zinman B, et al. Fifty-two-week efficacy and safety of vildagliptine vs, glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diab Obes Metab 2009;11:157-166
37. Schweizer A, Dejager S, Bosi E. Comparison of vildagliptine and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diab Obes Metab 2009;11:804-812